Author:

Keywords:

atrial tachycardia (AT), atrial tachycardia ablation, Cardiac & Cardiovascular Systems, Cardiovascular System & Cardiology, CATHETER ABLATION, CLINICAL-SIGNIFICANCE, FLUTTER, inducibility, INDUCTION, ISTHMUS, Life Sciences & Biomedicine, linear ablation, LINEAR ABLATION, MARSHALL ETHANOL INFUSION, outcomes, PREVALENCE, PULMONARY VEIN ABLATION, Science & Technology, STRATEGY, vein of Marshall ablation, 3201 Cardiovascular medicine and haematology

Abstract:

Recurrent atrial tachycardia (AT) is a common phenomenon after catheter ablation for AF, particularly in the setting of additional substrate ablation, with many studies demonstrating gap-related macro re-entrant AT (predominantly mitral and roof dependent) to be the dominant mechanism. Although multiple inducible ATs after ablation of the clinical AT are commonly described at repeat procedures, the optimal ablation strategy, and procedural endpoints are unclear in this setting. A recent randomized study addressing the question of non-inducibility as a procedural endpoint demonstrated no additional benefits to the ablation of all induced, non-clinical ATs, but it was limited by small numbers and high rates of non-inducibility. Nevertheless, once ablation of the clinical AT has been successfully performed, ensuring durable linear block and PV isolation may be sufficient for the prevention of further AT. Durable linear block, particularly at the mitral isthmus, is difficult to achieve but may be facilitated by the real-time evaluation of lesion quality and contiguity and the novel technique of vein of Marshall ethanol infusion. Large-scale, randomized trials are needed, nonetheless, to fully assess the optimal ablation strategy in the setting of recurrent AT post-AF ablation.